This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Alpine (ALPN) Down on FDA Partial Clinical Hold on Cancer Study
by Zacks Equity Research
The FDA places a partial clinical hold on Alpine's (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck's Keytruda for treating advanced malignancies. Shares fall.
Minerva Neurosciences (NERV) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 40% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 23.71% and 6.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Alpine Immune Sciences, Inc. (ALPN) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Small Biotech Stocks in Focus on World Arthritis Day
by Indrajit Bandyopadhyay
Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.
Alpine Immune Sciences, Inc. (ALPN) Surges 6.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Alpine Immune Sciences, Inc. (ALPN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -58.62% and 9.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Alpine Immune Sciences, Inc. (ALPN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alpine (ALPN) Enters Immuno-Oncology Collaboration With Merck
by Zacks Equity Research
Alpine (ALPN) signs a collaboration and supply deal with Merck to evaluate ALPN-202 in combination with the latter's Keytruda for treating various types of cancer.
Alpine Immune Sciences, Inc. (ALPN) Moves 9.5% Higher: Will This Strength Last?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -40.63% and -45.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Alpine (ALPN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Alpine (ALPN) stock based on the movements in the options market lately.
Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of 0.00% and 101.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Alpine (ALPN) Looks Good: Stock Adds 7.8% in Session
by Zacks Equity Research
Alpine (ALPN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
New Strong Sell Stocks for September 8th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
United Therapeutics (UTHR) Q2 Earnings In Line, Sales Beat
by Zacks Equity Research
United Therapeutics' (UTHR) second-quarter sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
Alpine Immune Sciences, Inc. (ALPN) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Alpine Immune Sciences, Inc. (ALPN).
4 Small Drug Stocks Worth Betting on Amid Coronavirus Woes
by Zacks Equity Research
Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.
Alpine Begins Dosing in Phase I Study for Advanced Malignancies
by Zacks Equity Research
Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.
Translate Bio Up on Vaccine Agreement Expansion With Sanofi
by Zacks Equity Research
Translate Bio (TBIO) and Sanofi expand their tie-up to develop mRNA vaccines for infectious diseases. The deal boosts the company's cash resources significantly along with potential future revenues.
Alpine Skyrockets on License Deal With AbbVie for ALPN-101
by Zacks Equity Research
Alpine (ALPN) signs an agreement with AbbVie granting exclusive worldwide option and license to its pipeline candidate, ALPN-101. The deal significantly boosts Alpine's funds.
Company News for Jun 19, 2020
by Zacks Equity Research
Companies in the news are: SPOT, ALPN, AESE, NEON
Alpine Immune Sciences' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Alpine Immune Sciences.